A Precision Workflow for Clinical Bioprinting – Presented by Paul Goodwin, GE Healthcare, Life Sciences

A Precision Workflow for Clinical Bioprinting – Presented by Paul Goodwin, GE Healthcare, Life Sciences, at the 3D Medical Conference, which takes place on January 30-31, 2019, at MECC Maastricht, The Netherlands.

Current bioprocess manufacturing focuses on biologic replacement therapies and monoclonal antibodies. We are at the beginning of a new wave of therapies wherein the cell is the therapy.

We have seen investments and advancements in T-cell therapies but if only address immunotherapy we will have missed a larger opportunity.

We present here the vision of a workflow to address the need to generate replacement structures, tissues, and organs that are living, bespoke, autologous, and regulated.

Interview
What drives you?
I believe that I have a moral responsibility to apply the talents that I have to improve the lives of those around me. We live in an incredible time where the confluence of new technology enables us to make substantive improvements in how therapies are discovered, manufactured, and delivered to patients. I am driven by the opportunities that I have to help enable those improvements.

What are the three things you would take with you on a deserted island?
A friend (my wife), a good knife, and a sturdy boat.

What emerging technologies/trends do you see as having the greatest potential in the short and long run?
First you have to ask “potential for what”. If you mean potential for positive impact on healthcare, I think the ability to manufacture therapeutic tissues and organs would be high on the list. Another emerging technology is the ability to assimilate patient data (genomics, clinical history, radiologic, biochemical, etc.) and, using artificial intelligence, derive new biomarkers for disease and therapeutic course.

What kind of impact do you expect them to have?
Clinical bioprinting will change the way that we treat chronic disease. Instead of a lifetime of drugs, therapies, and high healthcare costs we will replace failing organs with manufactured replacements.

New biomarkers for disease and therapy will enable the discovery, design, and delivery of more precise therapies with better specificity and fewer off-target effects. This is especially important in how we treat cancer, neurologic, and cardiovascular diseases.

What are the barriers that might stand in the way?
I think that coming up with the correct business models is a huge barrier. I don’t think any one entity can fully deliver on either goal. It will require that governments, companies, and individuals find a model in which everyone can pool resources and share in the rewards. That will not be easy.

Why should the delegate attend your presentation?
I think that it is important that we start to address not just specific technical challenges for innovation but to also look at the entire workflow and consider the interplay of technologies, biology, and regulatory requirements necessary to bring radically new therapies to clinical practice. We will take a look at a workflow for clinical bioprinting that attempts to address this need.

“Special Quote”
“If we always do what we’ve always done we will always get what we’ve always gotten” – Jessie Potter. This is a promise of consistency and precision and a threat to innovation.

About Paul Goodwin
I am part of a team of subject matter experts who evaluate new and emerging scientific and technology trends and make recommendations to the business regarding strategies and technical and business opportunities.

My education is in Physiology and Biophysics. I spent my career inventing, discovering, evaluating, and bringing to market new technologies that enable scientific and biomedical advancement.

My expertise is in microscopy, imaging, image analytics, and sensors. In 1987 I created the Image Analysis Laboratory at the Fred Hutchinson Cancer Research Center in Seattle, WA. From 1997 until 2011 I worked for Applied Precision, Inc. where I was served in a role similar to Chief Scientist. In 2011 we were purchased by GEHC, Life Sciences and in 2013 I moved into a technical leadership role within the CTO R&D organization.

About GE Healthcare, Life Sciences
At GE Healthcare Life Sciences, we strive to develop breakthrough products that inspire our customers to push the limits of imaginative science.

Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world.

For more information about 3D Medical Conference & Expo and registration, please visit https://3dmedicalconference.com/.

Leave a Reply

Your email address will not be published. Required fields are marked *